Cancer

Title
A Study Investigating the Addition of Pravastatin to Chemotherapy for the Treatment of Relapsed Acute Myelogenous Leukemia
Trial Number
203146111710
Number of Participants
50
Principal Investigator
Eligibility

Adults = 18 years of age with the following criteria may be eligible: morphologically confirmed diagnosis of acute myeloid leukemia (AML), at least one prior chemotherapy regimen given for their AML (They must have achieved complete remission (CR), lasting at least three months with their last induction regimen, and they must have relapsed after the last regimen.) and a Zubrod performance status of 0 - 2. Please see the protocol for additional requirements.

Purpose

The purpose of this study is to see what effects, good and/or bad, that adding pravastatin, a drug usually used to treat high cholesterol, to chemotherapy has on relapsed acute myelogenous leukemia.

Enrollment

(708) 327-2039

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.